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Abstract
Background: The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria
but no studies of its use for prevention have been done in Africa. We did a cluster randomized trial to determine whether
piperaquine in combination with either dihydroartemisin (DHA) or sulfadoxine-pyrimethamine (SP) is as effective, and better
tolerated, than SP plus amodiaquine (AQ), when used for intermittent preventive treatment in children delivered by
community health workers in a rural area of Senegal.
Methods: Treatments were delivered to children 3–59 months of age in their homes once per month during the
transmission season by community health workers. 33 health workers, each covering about 60 children, were randomized to
deliver either SP+AQ, DHA+PQ or SP+PQ. Primary endpoints were the incidence of attacks of clinical malaria, and the
incidence of adverse events.
Results: 1893 children were enrolled. Coverage of monthly rounds and compliance with daily doses was similar in all
groups; 90% of children received at least 2 monthly doses. Piperaquine combinations were better tolerated than SP+AQ
with a significantly lower risk of common, mild adverse events. 103 episodes of clinical malaria were recorded during the
course of the trial. 68 children had malaria with parasitaemia .3000/mL, 29/671 (4.3%) in the SP+AQ group, compared with
22/604 (3.6%) in the DHA+PQ group (risk difference 0.47%, 95%CI 22.3%,+3.3%), and 17/618 (2.8%) in the SP+PQ group (risk
difference 1.2%, 95%CI 21.3%,+3.6%). Prevalences of parasitaemia and the proportion of children carrying Pfdhfr and Pfdhps
mutations associated with resistance to SP were very low in all groups at the end of the transmission season.
Conclusions: Seasonal IPT with SP+PQ in children is highly effective and well tolerated; the combination of two long-acting
drugs is likely to impede the emergence of resistant parasites.
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Introduction
Although the incidence of malaria is declining in many parts of
Africa, it remains an important public health problem, especially in
poorer rural communities with limited access to health care. In
Senegal, in the Niakhar demographic Surveillance area in 2007, 31%
of deaths amongst children under 5 years were attributed to malaria
(A Marra personal communication). In areas of seasonal malaria
transmission, the burden of severe disease and mortality due to
malaria is mainly among children under 5 years of age. Intermittent
preventive treatment (IPT) with antimalarial drugs given to all
children once a month during the transmission season can provide a
high degree of protection against malaria [1]. Implementation of the
intervention, organized by local health services and delivered by
community health volunteers, has been highly effective in pilot
studies, well accepted by communities and achieved high coverage
[2]. The choice of an appropriate drug regimen is critical to the
success of IPT as a public health strategy. An important consideration
is the possible impact of IPT on the emergence and spread of drug
resistant parasites; the drug regimen must be safe and well tolerated,
and should provide sustained protection against malaria. Seasonal
IPT with sulfadoxine-pyrimethamine (SP) and one dose of artesunate
resulted in a 90% reduction in incidence of clinical malaria in a
trial in Senegal [3]. A second trial in Senegal [4] showed that a
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lives (SP and amodiaquine (AQ), the latter given over three days) was
more effective than SP with one or three doses of artesunate and
more effective than AQ with artesunate, in preventing malaria. Very
few children developed parasitaemia, so that the potential for drug
resistant parasites to emerge and spread was low. Although SP+AQ
was more efficacious than the artemisinin-containing regimens tested,
it was associated with a higher frequency of adverse events, especially
vomiting, as AQ has a bitter unpleasant taste.
Piperaquine, an antimalarial compound belonging to the 4-
aminoquinolines similar in chemical structure to chloroquine and
amodiaquine, has a long terminal half life which makes it
especially suitable for prevention and a potential alternative to
AQ for use in intermittent preventive treatment. Piperaquine was
first synthesised in France by Rhone-Poulenc (13228 RP) in 1963.
It was investigated for its potential in preventing malaria following
oral administration at monthly or longer intervals [5]. In a large
field trial in West Africa, 13228RP was given at subtherapeutic
doses to children and adults at fortnightly and monthly intervals in
combination with another bisquinoline compound 12494 RP, to
determine the duration of protection which was found to be about
3 weeks [6] and to treat uncomplicated malaria cases [7] but its
use was not pursued in Africa and Senegal continued to use
chloroquine for chemoprophylaxis for children under 15 yrs until
1992 [8]. However, piperaquine was adopted in China where it
had been independently synthesised in 1966. Piperaquine was used
for chemoprevention in Hainan Island Province from 1968 [9];
piperaquine combined with sulfadoxine, known as Preventive No
3, was developed when some chloroquine-resistant parasites were
found to be resistant to piperaquine, and this combination was
used from 1969 [10,11,12]. Large scale trials of piperaquine for
chemoprevention of falciparum and vivax malaria were conducted
in several provinces. In field trials undertaken conducted in
children and adults in Hainan Island province from 1972–74 [13],
piperaquine alone or combined with sulfadoxine was given
monthly during the main transmission season from June to
September. The period of protection from malaria was reported to
be about 20 days with both regimens. Side effects (headache,
listlessness and dizziness) were mild, and no serious side effects
were noted. Piperaquine replaced chloroquine as the recommend-
ed treatment for falciparum malaria in China in 1978. Over the
next 14 years, 214 tons of piperaquine, equivalent to 140,000,000
adult doses, were used for mass prophylaxis and treatment.
Piperaquine has similar pharmacokinetic properties to chloro-
quine. Once-daily dosing of piperaquine for 3 days results in a 3- to
7-fold accumulation [14] and a long terminal half life after three
daily doses of 33 days [15], making piperaquine especially suitable
for chemoprevention. Dihydroartemisinin-piperaquine (DHA+PQ)
has been developed as a fixed-dose combination antimalarial
(Artekin) by Holleykin Pharmaceuticals, China and has been
evaluated extensively as a treatment for uncomplicated clinical
malaria in large clinical trials in Southeast Asia, China and Rwanda
(reviewed by Myint et al. [16]), showing that the combination is safe,
well tolerated, and highly efficacious. DHA-PQ is being used
increasingly in Southeast Asia and is part of national treatment
recommendations in Cambodia and Vietnam. Duocotecxin (Holley,
China), containing 40 mg dihydroartemisinin and 320 mg piper-
aquinephosphatepertablet,ismarketedinseveralAfricancountries.
A GMP formulation of DHA+PQ is being developed by Sigma Tau
with support from the Medicines for Malaria Venture and should be
licensed in 2009. An artemisinin-containing drug combination is not
a natural choice for IPT because of the short half-life of artemisinins
and widespread use of artemisinins could facilitate the emergence
and spread of artemisinin resistant parasites damaging the usefulness
of this class of drugs in treating acute cases of uncomplicated and
complicated malaria. However, DHA+PQ is currently the only
licensed product containing PQ available for use. We therefore
compared the acceptability, efficacy and safety of combining PQ
with SP and compared this combination with DHA+PQ and
sulfalene-pyrimethamine plus AQ, for intermittent preventive
treatment in children in a rural area of Senegal.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
The study protocol was approved by the Ethics Committee of the
Senegalese Ministry of Health (Conseil National de Recherche en
Sante ´), and by the ethics committee of the London School of Hygiene
and Tropical Medicine. A Data Safety Monitoring Board monitored
the trial. After approval from community leaders had been obtained,
the study was explained to parents or guardians of eligible children.
Consent was documented by signature of the parent or guardian, or,
if they could not sign, by signature of a witness.
Study population and randomization
The study was conducted in the catchment area of Keur Soce
health post in Ndoffane district, a rural area of Senegal. After
meetings with health staff and community representatives, a census
of 29 villages was conducted in July 2007 to enumerate all children
under 5 years of age. The area was then divided into 33 circuits,
each circuit including approximately 60 children to be covered by
one community health worker who would deliver IPT drugs once
per month. Since acceptability is difficult to assess in the formal
setting of a trial, and because the method of delivery may affect
compliance and acceptability, drug treatments were delivered by
community workers at home, replicating as closely as possible the
conditions under which IPT would be delivered routinely in
Senegal. The community worker circuit was the unit of random-
ization to avoid contamination due to sharing of tablets within a
household. Circuits were randomized to receive either SP+PQ,
SP+AQ or DHA+PQ after being divided into two strata, one small
stratum comprising circuits in the central village of Keur Soce in
which the health post is located and where most houses have
electricity, and outlying villages forming the larger second stratum.
A community worker was assigned to each circuit, then the list of 33
circuits was randomized, using the random number generator in
Stata version 9 (Statacorp, Texas). Randomization was checked for
balance with respect to cluster size and distance from health centre
and repeated until a balanced randomization was achieved. In
September, each household was visited by local community health
workers and trial staff to explain the study to parents and guardians
of children aged 2 months to 5 years and to invite them to
participate. Children who did not have a history of allergy to study
drugs and whose parent or guardian provided consent were
recruited and, if the child was well, the first dose of the treatment
wasadministered. Ifthe childwasunwell,he/shewas referred tothe
clinic, children diagnosed with malaria were treated with AQ/AS,
children who did not have malaria received their IPT dose.
Drug delivery and administration
IPT was administered on three occasions (September, October
and November) covering the latter part of the malaria transmission
season. Once a month, the local community worker came to the
house of a study child to administer the first dose of the drug
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not present at the initial census were included if they were aged
2–59 months and if their parents gave consent. Treatment rounds
consisted of treatment over three days, the first dose was given or its
administration supervised by the community worker; tablets for
days 2 and 3 were left with the mother to give unsupervised. Dosing
was according to age. Anthropometric data from a survey of 2000
children resident in the study area undertaken in September 2004
(K Simondon, unpublished data) were used to estimate doses by age
that would avoid under-dosing and minimise over-dosing. Children
in the DHA-PQ arm received Duocotexcin tablets (40 mg
dihydroartemisinin and 320 mg piperaquine phosphate, Holley,
China), a half tablet if aged ,24 months, a whole tablet if aged 24
months or above. Children in the SP+PQ arm received piperaquine
tablets (250 mg piperaquine phosphate, Shanghai Pharmaceutical
Company, China), half tablet if under 12 months and a whole tablet
if 12 months or over, and sulfadoxine-pyrimethamine (500 mg
sulfadoxine and 25 mg pyrimethamine, Nestor Pharmaceuticals
Ltd, Faridabad, India), half tablet (,12 months), a whole tablet
(.=12 months). Children in the SP+AQ arm received Dualkin
(amodiaquine 200 mg half a tablet of amodiaquine (,24 months)
or a whole tablet (.=24 months), and sulfamethoxypirazyne
(sulfalene) 500 mg – pyrimethamine 25 mg, Pfizer, Dakar), half
a tablet (,12 months), or a whole tablet (.=12 months).
Sulfamethoxypirazyne is chemically very similar to sulfadoxine.
The predicted dose ranges of these dosing schedules obtained using
theanthropometricdatasetwere that 90% ofchildren would receive
daily doses between 9.4 and 19 mg/kg (amodiaquine); 28 to
58 mg/kg (sulfadoxine or sulfamethoxypirazyne); 1.4 to 2.9 mg/kg
(pyrimethamine); 15 to 30.5 mg/kg (piperaquine phosphate in the
Duocotexcin group); 14.2 to 29.2 mg/kg (piperaquine phosphate in
the SP+PQ group); and 1.9 to 3.8 mg/kg (dihydroartemisinin). As a
check on the actual dose received, 9 of the community workers were
given scales to record child weights at each treatment round.
Piperaquine was supplied by the Shanghai Pharmaceutical
Company and Duocotexcin by Holley, China. Both Dualkin and
Duocotexcin are licensed for treatment of uncomplicated malaria in
children; the combination SP+PQ is not licensed. To ensure com-
pliance with European regulations regarding drug quality, a sample
of piperaquine tablets was tested for drug content and impurities,
drug concentration was within 5% of the nominal level and analysis
of impurities indicated although some impurities exceeded the ICH
limit for known impurities [17], all these impurities were identified
and none were of concern in terms of safety.
Surveillance for malaria, compliance, and adverse events
Surveillance for malaria and adverse events that might have been
related to drug administration was maintained from September to
December 2007. Mothers or guardians of children in the study were
askedtotaketheirchildtoKeurSoce health postifthe childbecame
ill in any way during the period of the study. If the child had an
axillary temp .=37.5uC or a history of fever in the last 48 hours, a
finger prick blood sample was taken for malaria diagnosis by rapid
test and a blood film obtained to be read later. Children with a
positive test were treated with AQ/AS (according to national
guidelines for uncomplicated malaria), and did not receive the
scheduled IPT treatment that month. Children with a negative test
received the scheduled IPT treatment. In addition, one month after
each treatment round, before the next dose was given, trial staff
visited each child independently of the next treatment visit to check
the child’s health and, if the child had an axillary temperature
.=37.5uC the child was referred to the nearest dispensary and
managedasdescribedabove.InSeptember,allchildrenwere visited
4 days after the first treatment dose to record compliance with the
drug regimenand to ask the mother about any adverse events, using
a structured questionnaire. In October and November, a subsample
of 200 children in each arm of the trial were visited to record
compliance and adverse events on day 4. One month after the last
treatment, all children were visited to check for malaria symptoms
and to provide a finger prick blood sample for detection of malaria
parasitaemia, measurement of haemoglobin concentration and
investigation of the presence of parasite genotypes associated with
resistance to sulfadoxine and pyrimethamine. Passive surveillance
for malaria was maintained at the adjacent health post of Lamaram
during the period of the trial in order to provide an estimate of
malaria incidence in children who did not have IPT.
Laboratory methods
Children with suspected malaria were diagnosed using the
Paracheck-PfH test (Orchid Biomedical Systems, Goa, India),
diagnosis was confirmed if both control and test lines indicated a
positive result for P. falciparum, the test was repeated if the control
line did not appear. From the same sample, thick smear blood films
were stained with Giemsa and read twice. Slides were declared
negative if no parasites were seen after examining 100 microscope
fields. Four drops of blood were collected on filter paper, desiccated
and stored with silica gel for analysis of parasite genotype in the
laboratory of parasitology of the Cheikh Anta Diop University.
DNA was extracted from filter papers corresponding to the positive
slides by the hot methanol method and analyzed by PCR. For the
PfDHFR gene, point mutations at codons 51, 59 and 108 were
detected by Mutation Specific PCR as previously described [18,19].
For the PfDHPS gene, PCR RFLP was carried out to identify
mutations at codons 437 and 540 [19,20]. Products were analysed
using 1.5% agarose gel and visualised by UV illumination after
staining with ethidium bromide.
Endpoints
The primary endpoints were the cumulative incidence of
malaria (parasite density .=300/uL with an axillary temperature
.=37.5uC or a history of fever in the previous 48 hours), and the
proportion of children who experienced moderate or severe
adverse events. Secondary endpoints were malaria incidence with
any parasitaemia in the presence of fever or a history of fever,
compliance with and acceptability of the regimen, the prevalence
of parasitaemia, the mean haemoglobin concentration and the
prevalence of moderate (Hb,9 g/dL) and severe anaemia
(Hb,5 g/dL), and the proportion of children carrying parasite
genotypes associated with resistance to sulfadoxine or pyrimeth-
amine at the end of the transmission season (one month after the
final treatment round).
Sample size
Sample size was calculated for comparison of each treatment
group to the group who received SP+AQ, the best regimen
identified in the trial conducted previously in Niakhar [4]. Sample
size was chosen firstly to be able to establish non-inferiority with
respect to malaria incidence (we assumed an expected cumulative
incidence of malaria of 5% in all groups). On the basis of previous
studies, 40% of children in this population would be expected have
an episode of malaria each year [3]. We chose a non-inferiority
margin of 5%, and determined the sample size for 80% power and
95% confidence, and allowed for 10% loss to follow-up. For an
individually randomized trial, 355 children per group would be
required. Assuming an intraclass correlation (ICC) of 0.01, based
on the assumption that true malaria incidence will range from 0%
to 10% among clusters, and a cluster size of 60 children, then 10
clusters, i.e. 600 children, per treatment group were required. In
Piperaquine for IPTc
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experienced an adverse event in the week after IPT treatment.
Similar calculations to those described above indicated 20 clusters
of approximately 60 children the trial had at least 80% power to
detect a 50% reduction in the incidence of adverse events.
Statistical methods
A statistical analysis plan was written before the final database
was available. For safety endpoints, all children who received at
least one treatment dose were included. For efficacy endpoints
both according to protocol (ATP) and intention to treat (ITT)
analyses were performed. Children were included in the ATP
analysis if they were given the first dose of all three treatment
rounds, (regardless of whether day 2 and 3 doses were received).
Children who received the first daily dose but later vomited were
included in the ATP analysis, as were children who missed IPT in
a particular month because they were being treated for malaria on
the day IPT treatment was due. All children resident in the study
area, (those enumerated in the initial census and any children who
reached the age of 3 months during the trial or immigrated) and
were ,60 months of age at the September treatment round were
included in the ITT analysis of efficacy. To take account of the
cluster-randomized design, analysis was based on the (unweighted)
mean (for continuous variables) or proportion (for binary variables)
for each cluster [21]. Comparison of malaria incidence between
the treatment groups was based on the two-sided 95% confidence
interval for the risk difference [22,23]. Confidence intervals were
derived allowing for stratification [24]. Pre-specified covariates for
which adjustment was made were distance from the health centre,
age of the child and whether the child used a bednet (defined as
usually sleeping under a treated or intact net). Adjustment for
covariates was performed by the two-step method proposed by
Bennett et al. [25] using aggregated residuals from a regression
model fitted to the data for individuals. Secondary endpoints
(prevalence of parasitaemia and mean haemoglobin) were
analysed in a similar way, with adjustment for the same covariates.
The incidence of adverse events was compared using a stratified
t-test to compare cluster-level proportion of children who
experienced vomiting, fever, rash, itching or headache within
four days of treatment. Tests for interaction between intervention
group and age group on the risk of adverse events was carried out
as described by Cheung et al. [26], using predefined age groups
(,2 years and $2 years). Where appropriate, age-specific risk
differences were calculated; otherwise the age-adjusted risk
differences are shown. The proportion of children carrying P.
falciparum DHFR and DHPS genotypes associated with resistance
to SP was estimated as the product of the probability of being
slide-positive for P. falciparum and the probability of carrying
resistance genotype if slide-positive. Standard errors were
estimated from the standard errors for the two probabilities
using the delta method. The chi-squared test of homogeneity was
used to determine if there was an association between dose
administered (mg/kg bodyweight, grouped according to quartiles)
and the incidence of adverse events (mother’s report of vomiting,
fever, or any adverse event, recorded on day 4 after the treatment
round).
Results
Participant flow
1791 children under 5 years of age were enumerated in July
2008, six were lost to follow-up, three died, and an additional 70
children were recruited by the time of the first treatment round.
1257 of these children were included in the ATP analysis. 1893
children (including 34 who were recruited after the September
round) were included in the ITT analysis. Two clusters in the
SP+PQ arm received SP+AQ in error in September, these clusters
were excluded from the ATP analysis and included in the SP+PQ
arm in the ITT analysis. 1687 children were present at the final
survey in December (Figure 1). The three arms of the trial were
similar in terms of the number, age and gender of children, and
distance of houses from the health centre; bednet coverage
(defined as the child usually sleeping under an intact or treated net)
was slightly higher in the DHA+PQ arm (Table 1). The main
ethnic groups in the study area were Wolof, Peulh, Toucouleur
and Serere.
Coverage of IPT doses and adherence to drug regimen
The percentage of children who received three, monthly doses
of IPT from the community health-worker was similar in all
groups (overall 70%, Table 2). The main reason doses were missed
was the absence of families from the village at the time of the
treatment round. Almost all children (98%) who received the first
daily dose from a community worker were reported by the mother
to have been given the second and third doses at home, and of
these approximately 80% of the children were reported to have
swallowed the doses without difficulty. In October and November,
the proportion that swallowed all three doses without difficulty was
highest in the DHA-PQ group (in this group children had to
swallow only one tablet or half tablet). Among children who were
weighed, the 2.5% and 97.5% percentiles of the dose per kg
received (number of tablets divided by measured body weight at
the time of drug administration) were pyrimethamine 1.31 to
3.20 mg/kg, sulfalene 20.1 to 52.1 mg/kg, amodiaquine 8.0 to
20.8 mg/kg/day, sulfadoxine 26.1 to 64.0 mg/kg, piperaquine
(in SP+PQ group) 13.1 to 32.0 mg/kg/day, piperaquine (in
DHA+PQ group) 12.6 to 34.3 mg/kg/day, dihydroartemisinin
1.57 to 4.28 mg/kg/day.
Malaria incidence
103 episodes of malaria were recorded in 89 children
(cumulative incidence 4.7%, 89/1893, Table 3) 14 of whom had
a second episode. 34 of these cases were detected through passive
surveillance maintained at the health centre, the remaining cases
were detected through monthly active surveillance visits. Malaria
was suspected as the cause of death for 2 children who died at the
start of November, one in the SP-AQ group and one in the DHA-
PQ group. The October IPT dose had been refused in both cases.
48 children had malaria detected during the 3 month period when
IPT was given and an additional 41 new cases were detected at the
morbidity survey in December. No child had more than two
episodes of malaria. Incidence of malaria episodes over the study
period is shown in figure 2. 68 children had malaria with parasite
density .3000/uL. The risk of malaria was similar in all three
groups (the point estimates of malaria risk were slightly lower in
the group that received SP-PQ). 95% and 99% confidence
intervals for the risk difference between SP-PQ and SP-AQ
excluded the pre-specified inferiority margin of 5% in both the
ATP and ITT analyses. The 95% confidence interval for the risk
difference between DHA-PQ and SP-AQ also always excluded
5%. Both piperaquine containing regimens are thus non-inferior
to SP-AQ at the 95% confidence level.
In Lamaram health post, adjacent to the study area, there were
an estimated 117 cases of malaria in children under 5 years of age
during the period of the trial, detected by passive surveillance,
from a catchment population estimated to include 1088 children,
an incidence rate of 11%.
Piperaquine for IPTc
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Table 1. Baseline characteristics of treatment groups.
SP-AQ DHA-PQ SP-PQ
Number of children 654 598 607
Number of clusters 11 11 11
Mean cluster size (range) 59.5 (39–70) 54.5 (40–74) 55.2 (40–69)
Mean (sd) age (months) 29.3 (16.5) 30.1 (16.7) 29.3 (16.3)
Gender, % Male 48.2 (315/654) 45.3 (271/598) 47.5 (288/607)
Bednets: % sleeping under an intact or treated net 26.4 (172/651) 34.2 (204/597) 26.4 (160/607)
Mean distance (sd) of clusters from health centre 3.5 (2.5) 2.4 (2.0) 2.7 (1.9)
doi:10.1371/journal.pone.0007164.t001
Piperaquine for IPTc
PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7164Adverse events
Three children died before the September treatment round; six
children died during the intervention period. Deaths occurred at
home and the most likely cause of death was determined by verbal
autopsy. A pertussis outbreak occurred in the study area during
the trial; two girls in the SP-PQ group, aged 5 and 6 months, who
died in October, were suspected to have had pertussis. Two girls,
one aged 3 months in the SP-AQ group and one aged 4 months in
the DHA-PQ group died in September; death was attributed to
febrile diarrhoea. Two boys (one in the SP-AQ group aged 48
months and one in the DHA-PQ group aged 27 months) died
from a febrile illness suggestive of malaria at the start of
November.
No drug-related severe adverse events were reported. When the
mother or carer was asked about adverse events four days after the
first treatment round, fever, vomitting and headache were more
commonly reported in the SP+AQ group than in either of the PQ
groups (Table 4). Rash and itching were less commonly reported
and incidence was similar in all groups. For two symptoms,
vomiting and fever, there was a significant interaction between
treatment and age, reflecting the fact that in the SP+AQ group,
incidence of both symptoms was more common among children
over 2 yrs of age than among children under 2 years old, while in
the DHA-PQ and SP-PQ groups, these symptoms were similar in
each age group (fever) or slightly more common among under-2 yr
olds (vomiting). Results were similar after the second and third
treatment rounds (data not shown).
Association of adverse events with dose
When incidence of adverse events was examined in relation to
the dose received in the subset of children who were weighed,
there was a significant association with the incidence of vomiting
for amodiaquine, but there was no evidence of an association with
the risk of other adverse events, and no association of the risk of
Table 2. Compliance with monthly IPT schedule and adherence to 3-day regimens.
SP-AQ DHA-PQ SP-PQ
Number of monthly IPT doses from health-worker (N=654) (N=598) (N=607)
0 3.7% (24) 3.3% (20) 2.5% (15)
1 6.7% (44) 6.5% (39) 7.3% (44)
2 17% (109) 19% (112) 23% (142)
3 73% (477) 71% (427) 67% (406)
3 monthly IPT doses or malaria at time of IPT* 74% (485) 72% (433) 68% (410)
Compliance with 3-day IPT course
September
Given all 3 doses { 99% (685/694) 98% (546/559) 98% (443/454)
Swallowed all 3 doses { 78% (546/694) 81% (451/559) 82% (373/454)
October
Given all 3 doses 95% (155/164) 98% (161/165) 94% (139/148)
Swallowed all 3 doses 70% (115/164) 88% (145/165) 76% (113/148)
November
Given all 3 doses 94% (138/147) 95% (133/140) 93% (125/134)
Swallowed all 3 doses 71% (105/147) 93% (130/140) 78% (104/134)
*includes children who were seen at the monthly visit but did not receive IPT because they had malaria and were treated with an antimalarial.
{Denominator is children given IPT and followed up four days later. For September, treatment groups are of different sizes because two clusters received SP-AQ instead
of SP-PQ.
doi:10.1371/journal.pone.0007164.t002
Table 3. Cumulative incidence of malaria during the study period.
SP-AQ DHA-PQ SP-PQ
Malaria (.3000/ml), Intention to treat 4.3% (29/671) 3.6% (22/604) 2.8% (17/618)
Adjusted risk difference, %* (95%CI) Reference 20.47% (23.25%, 2.31%) 21.18% (23.64%, 1.28%)
(99%CI) (24.28%, 3.34%) (24.55%, 2.19%)
Malaria (.3000/ml), According to protocol 4.1% (20/485) 3.5% (15/433) 2.4% (8/339)
Adjusted risk difference, %* (95%CI) Reference 20.64% (23.18%, 1.9%) 21.53% (24.22%, 1.15%)
(99%CI) (23.98%, 2.69%) (25.06%, 1.99%)
Malaria (any parasitaemia) Intention to treat 5.4% (36/671) 5.3% (32/604) 3.4% (21/618)
Malaria (any parasitaemia) According to protocol 5.0% (24/485) 4.9% (21/433) 2.7% (9/339)
*Adjusted for age, bednet use and distance from health centre.
ICC for malaria .3000, 0.007, and for malaria any parasitaemia, 0.018.
doi:10.1371/journal.pone.0007164.t003
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received SP+AQ and for whom weights were recorded, 33%
received a daily dose of AQ .15 mg/kg (the prescribed number of
tablets per day divided by the weight in kg recorded the day
treatment was given), of these 41% (43/104) were reported to have
vomited during three days of treatment, compared to 26% (55/
208) who received doses ,15 mg/kg, an odds ratio of 2.0 (95%CI
1.2–3.2, P=0.008).
Prevalence of malaria parasitaemia and markers of SP
resistance
4.4% of protocol compliant children (56/1260) were parasite
positive at the December survey by microscopy (table 5).
Gametocytes were detected in only 11 children (4 in the SP+AQ
group, 5 in the DHA+PQ group and 2 in the SP+PQ group), an
overall prevalence of 0.9% (11/1260).
The overall number of children carrying P. falciparum parasites
with the triple Pfdhfr mutations associated with resistance to
pyrimethamine was very low in all groups (Table 5). Point
estimates were slightly lower in the groups that received
piperaquine. 21 of the 40 samples that were typed (53%) were
positive for the dhfr triple mutation and 15 (38%) for the dhps-437
mutation associated with resistance to sulphonamides.
Anaemia
27% of children (332/1222) enrolled in the study were
moderately anaemic (Hb,9 g/dL) in December; 14 children
were severely anaemic (Hb,5 g/dL) (table 6). Prevalence of
anaemia and of severe anaemia was greater among children who
received DHA-PQ than among those who received SP+AQ. Mean
haemoglobin concentration was lower among children who
received DHA+PQ than in the SP+AQ group (a difference in
Hb concentration, adjusted for covariates, of 0.46 g/dL, 95% CI
0.1 to 0.81 g/dL, in the ATP analysis and 0.38 (0.03 to 0.73) in the
ITT analysis).
Hb concentration in the SP+PQ group was similar to that in the
SP+AQ group.
Discussion
IPT in pregnant women, infants or children requires an
effective, well-tolerated drug regimen as many subjects who
receive treatment will not need it. IPT currently relies on SP, but
as resistance to SP is high in some countries where IPT is indicated
alternative drugs are required. Long-acting regimens are needed
to minimise dosing frequency and maximise cost effectiveness. The
long terminal half life and excellent tolerability of piperaquine
make it a suitable choice for IPT. This is the first study of its use
Figure 2. Malaria incidence during the study period. Incidence of first episode malaria associated with parasitaemia at any parasite density in
the study area between September-December 2007. Single red lines indicate median date of the IPT rounds in September, October and November.
Double red line indicates the median date of the December morbidity survey. One child had a second malaria episode in mid-November and 13
children had a second malaria episode detected at the survey in December (not shown).
doi:10.1371/journal.pone.0007164.g002
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for this purpose in West Africa in the mid 1960’s. PQ in
combination with SP or DHA was well tolerated, and was as
effective as SP+AQ in preventing malaria. Because of the previous
demonstration of the efficacy of IPT in children in Senegal it was
not considered appropriate to include a placebo group in this
study and it is, therefore, not possible to determine the efficacy of
the PQ containing combinations. However, comparison of the
results obtained in this study with those of the control group
included in the 2002 study of IPTc in the same area (cumulative
incidence of malaria 41%, [3] compared with incidences of 3.6%
and 2.8% in the PQ containing regimens in the current study)
suggests that efficacy was high. The incidence of malaria in the
area adjacent to the trial site, detected by passive surveillance, was
11%, this maybe compared to the incidence of 34 cases (2%) that
were detected by passive surveillance in the trial population, again
compatible with high efficacy of the regimens used in the trial.
A previous trial in Senegal showed that SP+AQ was more
effective than artemisinin combinations in preventing malaria in
children but that the use of AQ was associated with a higher
incidence of mild and moderate adverse events, of which fever,
vomiting, and headache were the most commonly reported [4]. In
the present study, these symptoms were significantly less common
in the DHA+PQ and SP+PQ groups than in the SP+AQ group.
The prevalence of asexual parasitaemia and of gametocytaemia
was very low in all treatment groups at the end of the transmission
season, reducing the potential impact of IPT on the spread of drug
resistant parasites. Less than 2% of children treated with SP+PQ
or DHA+PQ carried the triple Pfdhfr mutation associated with
resistance to pyrimethamine. These results are compatible with
the longer terminal half life of PQ (over 1 month) compared
to AQ (about 1 week), which may be important in preventing
recrudescence of SP-resistant parasites in children treated with SP,
and in preventing establishment of infections with parasites with
Table 5. Prevalence of parasitaemia and of molecular markers of resistance to SP at the end of the transmission season.
SP-AQ DHA-PQ SP-PQ
Percentage slide positive 5.3% (22/413) 4.8% (19/395) 3.3% (15/452)
Percentage of children (95%CI)* carrying:
dhfr triple mutation (51, 59, 108) 3.6% (0.7, 19.3) 1.5% (0.6, 3.7) 1.8% (0.5, 7.3)
dhps-437 1.8% (0.3, 9.7) 1.9% (0.8, 4.4) 1.5% (0.3, 6.4)
quadruple mutation 1.2% (0.2, 6.9) 0.7% (0.3, 2.2) 0.4% (0.02, 6.0)
Percentage of parasite-positive individuals carrying:
dhfr triple mutation(51, 59, 108) 67% (12/18) 31% (4/13) 56% (5/9)
dhps-437 33% (6/18) 39% (5/13) 44% (4/9)
quadruple mutation 22% (4/18) 15% (2/13) 11% (1/9)
*estimated as the product of the probability of being positive for P.falciparum and the probability of carrying resistant genotype if positive for P.falciparum, with
standard errors estimated from the standard errors for the two probabilities. The intra-class correlation coefficient for being slide positive was 0.088.
doi:10.1371/journal.pone.0007164.t005
Table 4. Incidence of solicited adverse events reported by mother or carer four days day after the first administration of IPT.
SP-AQ (N=694) DHA-PQ (N=559) SP-PQ (N=454)
Vomitted 218 (31%) 76 (14%) 76 (17%)
,24 months 26% (74/282) 17% (36/210) 21% (42/196)
Risk difference (95%CI) Reference 28.4 (218, 1.6) 25.6 (216, 5)
$24 months 35% (144/412) 12% (40/348) 13% (34/258)
Risk difference (95%CI) Reference 222.7 (232, 214) 222.1 (232, 213)
Fever 219 (32%) 98 (18%) 89 (20%)
,24 months 28% (79/282) 20% (42/210) 19% (37/196)
Risk difference (95%CI) Reference 25.9 (216.5, 4.7) 28.3 (219.6, 3)
$24 months 34% (140/412) 16% (56/348) 20% (52/258)
Risk difference (95%CI) Reference 217 (228, 25.5) 213 (225, 21.1)
Rash 14 (2%) 3 (0.5%) 5 (1.1%)
Risk difference (95%CI) Reference 21.2 (23.1, 0.6) 20.8 (22.8, 1.1)
Itching 27 (3.9%) 7 (1.3%) 8 (1.8%)
Risk difference (95%CI) Reference 22.7 (25.5, 0.1) 22.4 (25.4, 0.6)
Headache 87 (13%) 32 (5.7%) 18 (4%)
Risk difference (95%CI) Reference 26.7 (213.2, 20.1) 28.7 (215.6, 21.7)
Intraclass correlation coefficients for each outcome were as follows: vomiting 0.067, fever 0.078, rash 0.024, itching 0.039, headache 0.072. Risk differences were adjusted
for age, or presented stratified by age group when there was a signification interaction with age.
doi:10.1371/journal.pone.0007164.t004
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most parts of West Africa; limiting its use to IPT in combination
with PQ could extend the useful life of both drugs. A further
advantage of SP+PQ over SP+AQ is that its longer action may
provide some protection for children who miss monthly doses.
The prevalence of PfDHFR triple mutation was lower in this
study than in children who received IPT with SP+AQ or SP+AS
in the two previous trials in the same area [3,4]. Since 2004,
artemisinin combinations (AS+AQ) have been used for treatment
of uncomplicated malaria in Senegal. The possible impact of this
policy on the prevalence of parasite genotypes associated with
resistance to SP should be monitored.
DHA+PQ was similar to SP+PQ in terms of efficacy and
tolerability but DHA is not an ideal drug for IPT, it’s rapid
elimination from the body means that any preventive action of the
combination will rely solely on PQ increasing selection pressure for
PQ resistance. DHA may ensure rapid clearance of any
parasitaemia present at the time of treatment, but we found no
evidence that DHA+PQ was more effective than SP+PQ in terms
of clinical outcomes. It is probably not advisable to use the same
drug combination for treatment of children with acute clinical
malaria and for prevention. In communities where artemether+-
lumefantine or AQ+artesunate are first line treatments for malaria,
SP+PQ may be a good combination for prevention, reducing drug
pressure on the artemisinins whose major advantage is their rapid
mode of action. In communities where DHA+PQ is used for
treatment, SP+AQ may be an acceptable combination for
prevention although associated with a higher incidence of minor
side effects than SP+PQ. Where SP resistance is more marked, the
use of SP in IPT regimens may be less effective, there is therefore a
need for alternative long-acting antimalarials to be developed.
Anaemia was more common in the group that received
DHA+PQ, this may be a chance finding, previous studies have
not reported anaemia associated with DHA, although artemsinins
can case transient reduction in reticulocyte count [27].
Dosing by age resulted in some children receiving doses in excess
of the recommended dose for their body weight. In the SP+AQ
group children who were overdosed were more likely to report
adverse events; it is likely that this was due to AQ rather than SP
(overdosingwithSP+PQwasnot associatedwithanincreasedriskof
adverse events). It may, therefore, be possible to improve the
tolerability of SP+AQ by improving the accuracy of dosing.
Compliance with the second and third daily doses, given
unsupervised by the mother, was slightly better with the single-
tablet regimen (DHA+PQ) than with the other regimens.
Development of fixed dose coformulated tablets for IPT may
improve compliance. Single dose regimens would also be preferable
but the long action of PQ may require accumulation of
concentration over three days.
Many antimalarial treatments, including SP+AQ and SP+CQ,
have been adopted for clinical use and included in national
treatment policies without the formal programme of pharmaceu-
tical development now required by regulatory authorities for new
drugs or drug combinations, dosing schedules having been
established through clinical practice. Pharmacokinetic data for
piperaquine became available only comparatively recently [14,15].
PQ has a similar chemical structure to CQ and AQ, both of which
can be safely and effectively used in combination with SP, so an
interaction of PQ with SP is therefore highly unlikely. Preclinical
toxicological studies of PQ plus sulfadoxine were conducted in
China [28,29], and a number of clinical trials of this combination
have been reported [30,13]. Nevertheless pharmacokinetic studies
of SP+PQ in children may be required before widespread use of
the combination could be recommended.
This trial was not blinded, as use of dummy tablets would not
have been compatible with the pragmatic design. However,
malaria diagnosis relied on use of objective diagnostic tests and
laboratory staff who read blood films did not have access to
treatment assignments. Trial staff and parents were aware of the
child’s treatment group which could have influenced reporting and
assessment of adverse events, nevertheless as the trial was
conducted in an operational setting, the data obtained may give
a fair reflection of the acceptability of the regimens if they were to
be used routinely.
Coverage of treated bednets was low in the study area. Most trials
of IPTc have been conducted in areas where ITN coverage is low
and consequently there is limited information about the interaction
of IPT and ITNs, but it is likely that IPT would add to the
protection provided by bednets. In a randomized trial of ITNs and
chemoprophylaxis with dapsone/pyrimethamine, using a nested
factorial design, malaria incidence was significantly reduced in the
children who received chemoprophylaxis and ITNs compared to
children using ITNs alone [31]. A trial designed to estimate the
additional benefit of IPT in children using ITNs is currently
being conducted in Burkina Faso and Mali (clinicaltrials.gov
NCT00738946).
Two children who missed their October dose of IPT died in
early November, probably from malaria. Where IPT is introduced
efforts should be made to encourage families to ensure that their
children receive each monthly dose. Home management for
malaria, whereby antimalarial treatment is available (presump-
tively or after a positive RDT) at home or in the vicinity of the
home for children with a febrile illness, may be able to prevent
such deaths. Home management for malaria has been evaluated in
several countries [32] but studies of its use in combination with
IPT are needed.
The results of this trial support an increasing body of evidence
that seasonal IPT in children is a safe and highly effective strategy
for malaria prevention. SP+PQ is cheap and well tolerated and its
use could optimise the effectiveness of seasonal IPT. High
coverage and excellent compliance can be achieved when IPT is
delivered through local health services. Large scale implementa-
Table 6. Prevalence of anaemia and mean haemoglobin concentration at the end of the malaria transmission season.
SP-AQ DHA-PQ SP-PQ
Anaemia (Hb,9 g/dl) 23.3% (125/537) 34.3% (170/495) 27% (136/503)
Severe anaemia (Hb,5 g/dl) 0.7% (4/537) 2% (10/495) 1% (5/503)
Mean haemoglobin concentration (g/dL)* 10.07 9.63 9.85
Difference in mean Hb (g/dL) (95%CI) Reference 0.38 (0.03, 0.73) 0.06 (20.33,0.45)
*The ICC for Hb concentration was 0.041.
doi:10.1371/journal.pone.0007164.t006
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